Role of angiotensin II receptor blockers in atherosclerotic plaque stability

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 3, 2006, Pages 277-285

  Cipollone, Francesco ^a   Fazia, Maria Luigia ^a   Mezzetti, Andrea ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b Centro per lo Studio dell'Invecchiamento CeSI   (Italy)

Author keywords

Angiotensin II receptor blockers; Atherosclerosis; Inflammation; Plaque

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSINOGEN; APOLIPOPROTEIN E; C REACTIVE PROTEIN; CANDESARTAN; CHLORTALIDONE; COLLAGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE A; GELATINASE B; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; IRBESARTAN; PERINDOPRIL; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; RAMIPRIL; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CLINICAL TRIAL; DISEASE CONTROL; DOWN REGULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HISTOPATHOLOGY; HUMAN; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SODIUM EXCRETION; URINARY EXCRETION; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATHEROSCLEROSIS; BIPHENYL COMPOUNDS; CAROTID ARTERIES; COLLAGEN; CYCLOOXYGENASE 2; HUMANS; HYPERTENSION; MACROPHAGES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; RANDOMIZED CONTROLLED TRIALS; TETRAZOLES;

EID: 33144474495     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.3.277     Document Type: Review

References (65)

1. ROSS R: Atherosclerosis - an inflammatory disease. N. Engl. J. Med. (1999) 340(2):115-126.
2. LIBBY P: Inflammation in atherosclerosis. Nature (2002) 420(6917):868-874.
3. LIBBY P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation (2001) 104(3):365-372.
4. THE HOPE STUDY INVESTIGATORS: Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. (2000) 342(3):145-153.
5. WING LM, REID CM, RYAN P et al.: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. (2003) 348(7)583-592.
6. DAHLOF B, DEVEREUX RB, KJELDSEN S et al.: Cardiovascular morbility and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet (2002) 359(9311):995-1003.
7. PASTORE L, TESSITORE A, MARTINOTII S et al.: Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation (1999) 100(15):1646-1652.
8. ITOH H, MUKOYAMA M, PRATT RE, GIBBONS GH, DZAU VJ: Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J. Clin. Invest. (1993) 91(5):2268-2274.
9. VAUGHAN DE, LAZOS SA, TONG K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J. Clin. Invest. (1995) 95(3):995-1001.
10. SCHIFFRIN EL: Vascular and cardiac benefits of angiotensin receptor blockers. Am. J. Med. (2002) 113(5):409-418.
11. HORIUCHI M, AKISHITA M, DZAU VJ: Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension (1999) 33(2):613-621.
12. SESHIAH PN, WEBER DS, ROCIC P, VALPPU L, TANIYAMA Y, GRIENDLING KK: Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ. Res. (2002) 91(5):406-413.
13. RUIZ-ORTEGA M, LORENZO O, RUPEREZ M, KONIG S, WITTIG B, EGIDO J: Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ. Res. (2000) 86(12):1266-1272.
14. HAN Y, RUNGE MS, BRASIER AR: Angiotensin II Induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-κB transcription factors. Circ. Res. (1999) 84(6):695-703.
15. NABAH YN, MATEO T, ESTELLES R et al.: Angiotensin II induces neutrophil accumulation in viva through generation and release of CXC chemokines. Circulation (2004) 110(23):3581-3586.
16. KEIDAR S, HEINRICH R, KAPLAN M, HAYEK T, AVIRAM M: Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arterioscler. Thromb. Vasc. Biol. (2001) 21(9):1464-1469.
17. TANIYAMA Y, GRIENDLING KK: Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension (2003) 42(6):1075-1081.
18. CHIU JJ, WUNG BS, SHYY JY, HSIEH HJ, WANG DL: Reactive oxygen species are involved in shear stress-induced intercellular adhesion molecule-1 expression in endothelial cells. Arterioscler. Thromb. Vasc. Biol. (1997) 17(12):3570-3577.
19. RAJAGOPALAN S, MENG XP, RAMASAMY S, HARRISON DG, GALIS ZS: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Invest. (1996) 98(11):2572-2579.
20. CATALIOTO RM, RENZETTI AR, CRISCUOLI M, MORBIDELLI L, SUBISSI A: Role of calcium in angiotensin II-induced prostaglandin release and DNA synthesis in rat vascular smooth muscle cells. J. Cardiovasc. Pharmacol. (1996) 27(2):195-200,
21. OHNAKA K, NUMAGUCHI K, YAMAKAWA T, INAGAMI T: Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension (2000) 35(1 Pt 1):68-75.
22. TAKAGISHI T, MURAHASHI N, AZAGAMI S, MORIMATSU M, SASAGURI Y: Effect of angiotensin II and thromboxane A2 on the production of matrix metalloproteinase by human aortic smooth muscle cells. Biochem. Mol. Biol. Int. (1995) 35(2):265-273.
23. WEBER KT: Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation (1997) 96(11):4065-4082.
24. KUCHAREWICZ I, PAWLAK R, MATYS T, PAWLAK D, BUCZKO W: Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension (2002) 40(5):774-779.
25. HOSHIDA S, KATO J, NISHINO M et al.: Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndromes. Circulation (2001) 103(5):630-633.
26. SCHIEFFER B, SCHIEFFER E, HILFIKER-KLEINER D et al.: Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation (2000) 101(12):1372-1378.
27. KASCHINA E, UNGER T: Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. (2003) 12(2):70-88.
28. FOX KM; EUROPEAN TRIAL ON REDUCTION OF CARDIAC EVENTS WITH PERINDOPRIL IN STABLE CORONARY ARTERY DISEASE INVESTIGATORS: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet (2003) 362(9386):782-788.
29. LI J, HIROSE N, KAWAMURA M, ARAI Y: Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. Atherosclerosis (1999) 143(2):315-326.
30. LONN E, YUSUF S, DZAVIK V et al.: Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation (2001) 103(7):919-925.
31. PITT B, SEGAL R, MARTINEZ FA et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet (1997) 349(9054):747-752.
32. PITT B, POOLE-WILSON, SEGAL R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355(9215):1582-1587.
33. DICKSTEIN K, KJEKSHUS J; OPTIMAAL STEERING COMMITTEE OF THE OPTIMAAL STUDY GROUP: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet (2002) 360(9335):752-760.
34. PFEFFER MA, MCMURRAY JJ, VELAZQUEZ EJ et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. (2003) 349(20):1893-1906.
35. STRAWN WB, CHAPPELL MC, DEAN RH, KIVLIGHN S, FERRARIO CM: Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation (2000) 101(13):1586-1593.
36. LIANG C, WU ZG, DING J et al.: Losartan inhibited expression of matrix metalloproteinases in rat atherosclerotic lesions and angiotensin II-stimulated macrophages. Acta Pharmacol. Sin. (2004) 25(11):1426-1432.
37. DE LAS HERAS N, ARAGONCILLO P, MAESO R et al.: AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension (1999) 34(4 Pt 2):969-975.
38. JOHNSTONE MT, PEREZ AS, NASSER I et al.: Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model. Circulation (2004) 110(14):2060-2065.
39. 1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol. (2001) 38(3):395-405.
40. GALIS ZS, SUKHOVA GK, LARK MW, LIBBY P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. (1994) 94(6):2493-2503.
41. LOFTUS IM, NAYLOR R, GOODALL S et al.: Increased matrix-metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke (2000) 31(1):40-47.
42. CIPOLLONE F, PRONTERA C, PINI B et al.: Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation (2001) 104(8):921-927.
43. CORCORAN ML, STETLER-STEVENSON WG, DEWITT DL, WAHL LM: Effect of cholera toxin and pertussis toxin on prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases production by human monocytes. Arch. Biochem. Biophys. (1994) 310(2):481-488.
44. MATSUMOTO H, NARABA H, MURAKAMI M et al.: Concordant induction of prostaglandin E2 synthase with cyclooxygenase-2 leads to preferred production of prostaglandin E2 over thromboxane and prostaglandin D2 in lipopolysaccharide-stimulated rat peritoneal macrophages. Biochem. Biophys. Res. Commun. (1997) 230(1):110-114.
45. MITCHELL J, BELVISI M, AKARASEREENONT P et al.: Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br. J. Pharmacol. (1994) 113(3):1008-1014.
46. NEWNEWTON R, KUITERT LM, SLATER DM, ADCOCK IM, BARNES PJ: Cytokine induction of cytosolic phospholipase A2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids in human epithelial cells. Life Sci. (1997) 60(1):67-78.
47. MURAKAMI M, NARABA H, TANIOKA T et al.: Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem. (2000) 275(42):32783-32792.
48. MONCADA S, GRYGLEWSKI R, BUNTING S, VANE JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 263(5579):663-665.
49. FU JY, MASFERRER JL, SEIBERT K, RAZ A, NEEDLEMAN P: The induction and suppression of prostaglandin H2 synthase in human monocytes. J. Biol. Chem. (1990) 265(28):16737-16740.
50. HOLMES DR, WESTER W, THOMPSON RW, REILLY JM: Prostaglandin E2 synthesis, and cyclooxygenase expression in abdominal aortic aneurysms. J. Vasc. Surg. (1997) 25(5):810-815.
51. ARIAS-NEGRETE S, KELLER K, CHADEE K: Proinflammatory cytokines regulate cyclooxygenase-2 expression in human macrophages. Biochem. Biophys. Res. Commun. (1995) 208(2):582-589.
52. BURLEIGH ME, BABAEV VR, OATES JA et al.: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation (2002) 105(15):1816-1823.
53. CIPOLLONE F, FAZIA M, IEZZI A et al.: Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation (2004) 109(12):1482-1488.
54. STARY HC, CHANDLER AB, DINSMORE RE et al.: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation (1995) 92(5):1355-1374.
55. REKHTER MD: Collagen synthesis in atherosclerosis: too much and not enough. Cardiovasc. Res. (1999) 41(2):376-384.
56. FITZGERALD GA: Coxibs and cardiovascular disease. N. Engl. J. Med. (2004) 351(17):1709-1711.
57. DRAZEN JM: COX-2 inhibitors - a lesson in unexpected problems. N. Engl. J. Med. (2005) 352(11):1131-1132.
58. BELTON O, BYRNE D, KEARNEY D, LEAHY A, FITZGERALD DJ: Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation (2000) 102(8):840-845.
59. MARX N, SCHÖNBECK U, LAZAR MA, LIBBY P, PLUTZKY J: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. (1998) 83(11):1097-1103.
60. NAVALKAR S, PARTHASARATHY S, SANTANAM N, KHAN BV: Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J. Am. Coll. Cardiol. (2001) 37(2):440-444.
61. 1 receptor function and density in hypercholesterolemic men. Circulation (1999) 100(21):2131-2134.
62. HORIUCHI M, CUI TX, LI Z et al.: Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation (2003) 107(1):106-112.
63. CIPOLLONE F, FAZIA M, IEZZI A et al.: Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation (2003) 107(11):1479-1485.
64. NISSEN SE, TUZCU EM, LIBBY P et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The Camelot study: a randomized controlled trial. JAMA (2004) 292(18):2217-2226.
65. ZANCHETTI A, BOND G, HENNIG M et al.: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation (2002) 106(19):2422-2427.